Why has SGS’ Life Science Services combined with aster.cephac?
Since its establishment in 1975, aster.cephac has become one of the most well known providers of early clinical research services (full service Phase I-IIa). Thanks to our high-quality services and broad range of expertise and experience, aster.cephac represents an excellent development in SGS’ Life Science Services strategy, which is to be a world leader in early clinical research. Furthermore, aster.cephac’s dynamic management team and open culture are both compatible with SGS’ values and will help ensure a smooth integration. 2. What are the advantages to aster.cephac’s current service offering? aster.cephac’s service offering will be expanded in several areas, to the advantage of our customers: • Early phase: SGS will add the following services to aster.cephac’s current offering: radiolabeled ADME trials, special populations (renally impaired, hepatically impaired, pediatric trials, postmenopausal women, sterilised women, elderly, slow metabolisers) and patients for Proof-of-Concep
